Hicks Andrew A, Pramstaller Peter P, Johansson Asa, Vitart Veronique, Rudan Igor, Ugocsai Peter, Aulchenko Yurii, Franklin Christopher S, Liebisch Gerhard, Erdmann Jeanette, Jonasson Inger, Zorkoltseva Irina V, Pattaro Cristian, Hayward Caroline, Isaacs Aaron, Hengstenberg Christian, Campbell Susan, Gnewuch Carsten, Janssens A Cecilej W, Kirichenko Anatoly V, König Inke R, Marroni Fabio, Polasek Ozren, Demirkan Ayse, Kolcic Ivana, Schwienbacher Christine, Igl Wilmar, Biloglav Zrinka, Witteman Jacqueline C M, Pichler Irene, Zaboli Ghazal, Axenovich Tatiana I, Peters Annette, Schreiber Stefan, Wichmann H-Erich, Schunkert Heribert, Hastie Nick, Oostra Ben A, Wild Sarah H, Meitinger Thomas, Gyllensten Ulf, van Duijn Cornelia M, Wilson James F, Wright Alan, Schmitz Gerd, Campbell Harry
Institute of Genetic Medicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy.
PLoS Genet. 2009 Oct;5(10):e1000672. doi: 10.1371/journal.pgen.1000672. Epub 2009 Oct 2.
Sphingolipids have essential roles as structural components of cell membranes and in cell signalling, and disruption of their metabolism causes several diseases, with diverse neurological, psychiatric, and metabolic consequences. Increasingly, variants within a few of the genes that encode enzymes involved in sphingolipid metabolism are being associated with complex disease phenotypes. Direct experimental evidence supports a role of specific sphingolipid species in several common complex chronic disease processes including atherosclerotic plaque formation, myocardial infarction (MI), cardiomyopathy, pancreatic beta-cell failure, insulin resistance, and type 2 diabetes mellitus. Therefore, sphingolipids represent novel and important intermediate phenotypes for genetic analysis, yet little is known about the major genetic variants that influence their circulating levels in the general population. We performed a genome-wide association study (GWAS) between 318,237 single-nucleotide polymorphisms (SNPs) and levels of circulating sphingomyelin (SM), dihydrosphingomyelin (Dih-SM), ceramide (Cer), and glucosylceramide (GluCer) single lipid species (33 traits); and 43 matched metabolite ratios measured in 4,400 subjects from five diverse European populations. Associated variants (32) in five genomic regions were identified with genome-wide significant corrected p-values ranging down to 9.08x10(-66). The strongest associations were observed in or near 7 genes functionally involved in ceramide biosynthesis and trafficking: SPTLC3, LASS4, SGPP1, ATP10D, and FADS1-3. Variants in 3 loci (ATP10D, FADS3, and SPTLC3) associate with MI in a series of three German MI studies. An additional 70 variants across 23 candidate genes involved in sphingolipid-metabolizing pathways also demonstrate association (p = 10(-4) or less). Circulating concentrations of several key components in sphingolipid metabolism are thus under strong genetic control, and variants in these loci can be tested for a role in the development of common cardiovascular, metabolic, neurological, and psychiatric diseases.
鞘脂作为细胞膜的结构成分以及在细胞信号传导中发挥着重要作用,其代谢紊乱会引发多种疾病,产生不同的神经、精神和代谢后果。越来越多的证据表明,参与鞘脂代谢的几种酶的编码基因中的变异与复杂疾病表型相关。直接实验证据支持特定鞘脂种类在几种常见的复杂慢性疾病过程中发挥作用,包括动脉粥样硬化斑块形成、心肌梗死(MI)、心肌病、胰腺β细胞功能衰竭、胰岛素抵抗和2型糖尿病。因此,鞘脂代表了用于遗传分析的新的重要中间表型,但对于影响其在普通人群中循环水平的主要遗传变异知之甚少。我们在318,237个单核苷酸多态性(SNP)与循环鞘磷脂(SM)、二氢鞘磷脂(Dih-SM)、神经酰胺(Cer)和葡萄糖神经酰胺(GluCer)单一脂质种类(33个性状)之间进行了全基因组关联研究(GWAS);并在来自五个不同欧洲人群的4400名受试者中测量了43种匹配的代谢物比率。在五个基因组区域中鉴定出了相关变异(32个),其全基因组显著校正p值低至9.08×10⁻⁶⁶。在功能上参与神经酰胺生物合成和运输的7个基因中或其附近观察到了最强的关联:SPTLC3、LASS4、SGPP1、ATP10D和FADS1 - 3。在三项德国MI研究系列中,3个位点(ATP10D、FADS3和SPTLC3)的变异与MI相关。参与鞘脂代谢途径的23个候选基因中的另外70个变异也显示出关联(p = 10⁻⁴或更低)。因此,鞘脂代谢中几种关键成分的循环浓度受到强大的遗传控制,并且可以测试这些位点的变异在常见心血管、代谢、神经和精神疾病发展中的作用。